Drug Companies Update Oct 2007
Mergers, acquisitions & Joint Ventures
- Biotechnology company Genzyme, has acquired Bioenvision, a company focused on the development of anticancer therapeutics.
- Inhibitex, a biopharmaceutical company focused on the development of drugs to treat or prevent infectious diseases, has acquired FermaVir.
- Isis Pharmaceuticals has acquired Symphony Genisis.
- Mitsubishi Pharma and Tanabe Seiyaku have merged to form Mitsubishi Tanabe Pharma.
- NeuroBiotec, a pharmaceutical company specializing in CNS products has changed its name to Axxonis.
- Wyeth has acquired Haptogen, which will become a subsidiary known as Wyeth Protein Therapeutics Laboratories.
New Companies
- Araborex is a biotechnology company focused repurposing existing drugs for metabolic disease.
- BAS Medical is a biotechnology company focused on developing clinical applications for relaxin.
- Bio-Cancer Treatment is focused on developing biopharmaceuticals for the treatment of cancer
- Bio-Ker is developing biosimilars, recombinant proteins, controlled-delivery systems and therapeutic plasmid DNA vaccines.
- Biomet is engaged in the development and manufacturing of implants to replace hips, knees, shoulders and elbows.
- Canopus BioPharma is an internaltionally-based company developing pharmaceuticals, vaccines, diagnostics, camel blood products and nutraceuticals.
- CG Therapeutics is a biotechnology company developing cancer therapeutics focused on inhibiting hCG.
- Dara Biosciences is a development-stage pharmaceutical company that focuses on the development of small molecules from late preclinical to Phase II, in a range of therapeutic areas.
- Danish-based Egalet develops enhanced proprietary produces by applying its novel oral, erosion-based controlled-release technology.
- Denka Seiken is a Japanese manufacturer of vaccines and diagnostic agents.
- Egret Pharma is a pharmaceutical company engaged in developing treatments for diabetes
- Emcure Pharmaceuticals is focused on API, formulations and biotechnologies
- Biotechnology company, Flutrends is focused on the development of products for the treatment of influenza.
- Ichor Medical Systems develops DNA-based therapeutics in 3 areas: therapeutic proteins, anti-infective vaccines and cancer vaccines.
- Privately-owned InViragen is engaged in developing vaccines against emerging infectious diseases.
- Mercia Pharma is a New York-based biopharmaceutical company, developing immunotherapeutics.
- Medeia Therapeutics focuses on discovering and developing novel therapeutics for neurodegenerative diseases.
- Mersana Therapeutics is focused on the development of anticancer compounds using its Fleximer drug delivery technology.
- Multi Gene Vascular Systems develops cell-based therapeutics targeting heart and blood vessel disorders.
- Privately-owned Oxford Genome Sciences is focused on the development of personalized medicines.
- Serentis intends to establish a clinical stage development pipeline that will rapidly enter proof-of-concept studies.
- Syntrix Biosystems is a biotechnology company dedicated to the development and commercialization of therapeutic compounds and research platforms.
- ShimodaAtlantic Oncology Biosciences develops phytotherapeutics, nanotherapeutics and vaccines based on cytokeratin for the treatment of cancer.
- TissueGene is engaged in the development of regenerative medicine for the treatment of degenerative diseases.
- Zensun (Shanghai) Sci & Tech Co. is a biotech pharmaceutical company devloted to the research and development of anti-tumour and –heart failure drugs.
